Intellia stock rises on FDA priority review (NTLA:NASDAQ)
· seekingalpha.com
Intellia Therapeutics (NTLA) stock gains on FDA priority review for lonvo-z, a gene editing therapy for a rare condition called hereditary angioedema. Read more here.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
If you have an ad-blocker enabled you may be blocked from ...